BupPractice

DATA 2000 Qualifying Buprenorphine Training

Home › Training › Waiver Training for NPs & PAs Part 1: Buprenorphine Training
Price: $199

Waiver Training for NPs & PAs Part 1: Buprenorphine Training

Goal: To provide a core training to Nurse Practitioners and Physician Assistants who meet the requirement of the federal CARA 2016 law (which includes an 24 hour training experience), in order to increase the number of providers who are knowledgeable about and qualified to prescribe buprenorphine to their patients with opioid use disorder.
  or  Register

This activity is designed to change: Competence, Performance, Patient Outcome.  9hr(s)

Overview

Professional Practice Gaps

Educational Objectives:

After completing this activity participants will be able to:

  • Expand your practice to comply with the regulations and requirements of office-based buprenorphine treatment so that you can prescribe buprenorphine to your patients when appropriate
  • Relate buprenorphine’s pharmacological properties to its drug effects and understand the physiological effects of opioids and opioid treatments on patients
  • Identify, assess, and diagnose opioid use disorder in your patients
  • Use medical and substance use disorder history information to assess your patients in terms of suitability for treatment with buprenorphine
  • Provide effective and successful treatment to your patients throughout the phases of buprenorphine treatment: induction, maintenance, and discontinuation, and deal with complications that arise
  • Assess and adapt treatment guidelines to best treat your patients from specific patient populations, including those with psychiatric comorbidities, adolescents, the elderly, pregnant women, methadone transfers, and patients with pain
  • Prescribe, refer, or implement appropriate psychosocial therapies for treating opioid use disorder for your patients

Modules in this Training Activity

  • About Prescribing Buprenorphine v4.0
  • Impact of Opioid Use Disorder v4.0
  • Pharmacology of Buprenorphine and Other Opioids v4.0
  • Detection and Diagnosis of Opioid Use Disorder v4.0
  • Assessing Patients for Buprenorphine Treatment v4.0
  • Buprenorphine Protocol: Induction v4.0
  • Buprenorphine Protocols: Maintenance and Discontinuation v4.0
  • Buprenorphine Protocols: Methadone Patients and Other Subpopulations v4.0
  • Managing Patients in a Buprenorphine Practice v4.0
  • Regulations for Office-Based Opioid Treatment v4.0

Training Activity References

Audience and Accreditation

Audience: Providers

Type Est. Time Released Expires
DCBN 9 hr(s) 4/16/18 4/15/21
FAPA 9 hr(s) 4/16/18 4/15/21

DCBN Credit Statement: Clinical Tools, Inc. designates this enduring material for a maximum of 9 hour(s) of DCBN credit. Clinical Tools, Inc. is an approved provider by the District of Columbia Board of Nursing and is registered with CE Broker, Provider #50-1942.

FAPA Credit Statement: Clinical Tools, Inc. designates this enduring material for a maximum of 9 hour(s) of FAPA credit. Providers and other health professionals should claim only the credit commensurate with the extent of their participation in the activity.

A letter of completion for up to 9 hour(s) is available for non-physicians.

A score of 70% on the post-test is required to complete the activity.

Participation Requirements

Funding
Initial development of this activity was supported by a grant from the National Institute on Drug Abuse (#R44-DA12066).

Authors

As an ACCME accredited provider of continuing medical education, Clinical Tools, Inc.requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest to the provider. The ACCME defines ‘relevant’ financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Any conflicts of interest are resolved prior to the delivery of the educational activity to the learner. CTI does not permit individuals with financial conflicts of interest to participate in any stage of activity development.

T Bradley Tanner, MD (President, Clinical Tools, Inc.)
Disclosure: Has disclosed no relevant financial relationships. Dr. Tanner is the owner of Clinical Tools.
Karen Rossie, DDS, PhD (Research Scientist, Clinical Tools, Inc. )
Disclosure: Has disclosed no relevant financial relationships.

Reviewers

Judith Martin, MD (President of California Society of Addiction Medicine (CSAM) and Medical Director, BAART Turk Street Clinic)
Disclosure: Has disclosed no relevant financial relationships.
Steve Applegate, MEd, MEd (President, Applegate Consulting, )
Disclosure: Has disclosed no relevant financial relationships.

Most Recent Reviews

CTI Content Review: Thu, 11/21/2018
CTI Editorial Review: Mon, 11/29/2018